GRIFOLS SA-ADR
GRFSNASDAQTrading Snapshot
- Day Range
- $326.90 β $332.80
- 52-Week Range
- $6.96 β $10.23
- Volume
- $3.76B
- Avg Volume
- $3.88B
- Shares Outstanding
- 846.0M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $7.23B
- Last Q Revenue
- $1.87B
- P/E Ratio
- 14.3
- P/S Ratio
- 0.9x
- EPS (TTM)
- $0.66
- Dividend Yield
- 0.86%
- Dilution (1yr)
- +0.0%
Why Investors Own GRFS
- βHigh-growth profile β revenue up +16.7% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GRIFOLS SA-ADR
GRFSAbout GRIFOLS SA-ADR
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
GRIFOLS SA-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift GRFS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
GRIFOLS SA-ADR announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.